Infliximab in the treatment of rheumatoid meningoencephalitis.
Luessi
Felix
F
Sollors
Janina
J
Müller
Harald
H
Stoeter
Peter
P
Sommer
Clemens
C
Vogt
Thomas
T
Birklein
Frank
F
Thömke
Frank
F
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000175:diagnosis / Q000276:immunology; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D000069285:Infliximab; D008590:Meningoencephalitis / Q000188:drug therapy* / Q000209:etiology* / Q000276:immunology; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab
Neurology. 2007 Mar 27;68(13):1079-80
17389318
J Rheumatol. 2005 Jan;32(1):181-3
15630746
Ann Rheum Dis. 2006 Aug;65(8):1114-6
16837495
J Neurol. 2004 Jun;251(6):760-1
15311358
Arthritis Rheum. 1988 Mar;31(3):315-24
3358796
Clin Rheumatol. 2003 Dec;22(6):475-80
14677033
Semin Arthritis Rheum. 1989 May;18(4):258-66
2658068